Last update 04 Nov 2024

Onasemnogene abeparvovec

Overview

Basic Info

Drug Type
AAV based gene therapy
Synonyms
ChariSMA, onasemno-gene abepar-vovec, Onasemnogene abeparvovec (USAN/INN)
+ [9]
Target
Mechanism
SMN1 gene stimulants(survival of motor neuron 1, telomeric gene stimulants)
Inactive Indication-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (24 May 2019),
RegulationOrphan Drug (US), Breakthrough Therapy (CN), Orphan Drug (KR), Orphan Drug (AU)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HMN (Hereditary Motor Neuropathy) Proximal Type I
KR
28 May 2021
Spinal Muscular Atrophy
US
24 May 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Juvenile Spinal Muscular AtrophyPhase 3
US
10 Feb 2020
Juvenile Spinal Muscular AtrophyPhase 3
JP
10 Feb 2020
Juvenile Spinal Muscular AtrophyPhase 3
AU
10 Feb 2020
Juvenile Spinal Muscular AtrophyPhase 3
BE
10 Feb 2020
Juvenile Spinal Muscular AtrophyPhase 3
CA
10 Feb 2020
Juvenile Spinal Muscular AtrophyPhase 3
FR
10 Feb 2020
Juvenile Spinal Muscular AtrophyPhase 3
IT
10 Feb 2020
Juvenile Spinal Muscular AtrophyPhase 3
TW
10 Feb 2020
Juvenile Spinal Muscular AtrophyPhase 3
GB
10 Feb 2020
Muscular Atrophy, Spinal, Type IIPhase 3
US
10 Feb 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
24
courehohnt(pshbcrhguq) = ccfmzjdvim elkdnzdfpk (dipfbfmfah, 4.0)
Positive
04 Mar 2024
Phase 4
16
zribztvdky(xioamqpbma) = fkcxmsxkeu lfckuwxduv (gtgogtsszr )
Positive
03 Mar 2024
Not Applicable
-
-
vxkistqwmx(odpzthllsb) = Adverse events were recorded for two patients. None were serious and treatment-related, and event types were consistent with the established safety profile of OA rmjtkpmxcs (viwolbqopo )
-
03 Mar 2024
Not Applicable
-
defchmznri(snkzfxtnwp) = Troponin I elevations observed in OA-treated patients in RESTORE appear to be transient and self-limiting and were not associated with clinically concerning cardiac adverse events zxubvxcgvr (tudiiotavk )
-
03 Mar 2024
Not Applicable
31
cgktapvoph(ryfczfkcrh) = Two deaths were recorded, neither related to treatment lyraynmufs (aupqrdmliv )
Positive
03 Mar 2024
Not Applicable
-
Onasemnogene abeparvovec (OA)
xantenhddr(tnjipbqqvw) = xascdhbnrn ythkkwpagu (vyvajmdqwo )
-
03 Mar 2024
Risdiplam (EVRYSDI)
xantenhddr(tnjipbqqvw) = rpirlibwjm ythkkwpagu (vyvajmdqwo )
Phase 3
29
gzjkmqzmdx(zjjviysexp) = zzwrrtptsr yvyzaitkqq (obyelbbrwv )
-
25 Apr 2023
gzjkmqzmdx(zjjviysexp) = ymqiwksabq yvyzaitkqq (obyelbbrwv )
Phase 3
81
dlffmnvdrz(bkxfdoaaip) = The most frequently reported TEAEs were gastroenteritis, nasopharyngitis, pneumonia, respiratory distress, and viral infection blxiscnxko (ovetevgdlu )
Positive
25 Apr 2023
Intrathecal onasemnogene abeparvovec
Not Applicable
-
avcxrsqojz(nxsqeynqcw) = uwucsnopaq isvqjelzdc (tqybnybzga )
-
25 Apr 2023
Not Applicable
81
Intrathecal Onasemnogene Abeparvovec
mdlkmuyrms(tqucakykkz) = hprilogjzz zzqgvuwnho (yimpddmwgz )
-
19 Mar 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free